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Abstract
Background: The role of the epidermal growth factor receptor (EGFR) and other receptor tyrosine kinases (RTKs) in
provoking biological actions of G protein-coupled receptors (GPCRs) has been one of the most disputed subjects
in the field of GPCR signal transduction. The purpose of the current study is to identify EGFR-mediated
mechanisms involved in activation of G protein cascades and the downstream transcription factors by
lysophosphatidic acid (LPA).
Results: In ovarian cancer cells highly responsive to LPA, activation of AP-1 by LPA was suppressed by inhibition of
EGFR, an effect that could be reversed by co-stimulation of another receptor tyrosine kinase c-Met with hepatocyte
growth factor, indicating that LPA-mediated activation of AP-1 requires activity of a RTK, not necessarily EGFR.
Induction of AP-1 components by LPA lied downstream of Gi, G12/13, and Gq. Activation of the effectors of Gi, but
not Gq or G12/13 was sensitive to inhibition of EGFR. In contrast, LPA stimulated another prominent transcription
factor NF-B via the Gq-PKC pathway in an EGFR-independent manner. Consistent with the importance of Gi-
elicited signals in a plethora of biological processes, LPA-induced cytokine production, cell proliferation, migration
and invasion require intact EGFR.
Conclusions: An RTK activity is required for activation of the AP-1 transcription factor and other Gi-dependent
cellular responses to LPA. In contrast, activation of G12/13, Gq and Gq-elicited NF-B by LPA is independent of
such an input. These results provide a novel insight into the role of RTK in GPCR signal transduction and biological
functions.
Background
Lysophosphatidic acid (LPA, 1-acyl-sn-glycerol-3-phos-
phate) is a naturally occurring intercellular mediator of
diverse biological functions [1]. It is produced by acti-
vated platelets during coagulation and thus is a normal
constituent of serum [2,3]. At least six G protein-
coupled receptors (GPCRs) of LPA have been identified
[4]. The LPA1/Edg2, LPA2/Edg4 and LPA3/Edg7 recep-
tors are members of the endothelial differentiation gene
(Edg) family and share 50-57% homology in their amino
acid sequences [5-7]. Recently, LPA4/p2y9/GPR23,
LPA5/GPR92 and LPA6/p2y5 of the purinergic receptor
family, structurally distant from the Edg LPA receptors
were described as additional LPA receptors [8-11]. The
LPA receptors couple to multiple G proteins, G12/13,
Gi, Gq, and probably Gs [4]. These G proteins link to
diverse signaling pathways including stimulation of
phospholipase C and D, inhibition of adenylyl cyclase,
and activation of Ras and the downstream mitogen-acti-
vated protein kinases and phosphoinositide 3-kinase
[4,12]. Activation of these signaling cascades down-
stream of LPA receptors culminates in morphological
changes and promotion of cell growth, survival and
motility. Recently, we and others demonstrated that
LPA induces activation of various transcription factors,
upregulating expression of many target genes involved
in cell proliferation, survival, and migration and invasion
[13-20]. The connection of LPA and its receptors to
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research to understand the molecular mechanisms of
LPA signal transduction.
Many biological effects of GPCR have been thought to
occur through transactivation of EGFR [21,22]. In our
previous studies, however, the effects of LPA on gene
expression were much more potent than those of EGF
or other agonists of receptor tyrosine kinases (RTKs)
[15,19]. LPA indeed induced low levels of tyrosine phos-
phorylation of EGFR which were in no means compar-
able to that stimulated by EGF itself [19,23].
Intriguingly, the effect of LPA on its target gene Cox-2
was sensitive to inhibition of EGF, suggesting require-
ment of a permissive or parallel input from EGFR in the
delivery of signals of LPA or other GPCR agonists
[18,19]. In the current study, we explored the role of
RTK in LPA activation of G protein signaling cascades
and the downstream transcription factors. Molecular
and pharmacological studies indicated that activation of
the effectors of Gi, but not those of Gq or G12/13 relied
on EGFR. Furthermore, activation of AP-1 components
by LPA involved Gi signaling and was highly sensitive to
inhibition of EGFR. We further demonstrated that this
mode of crosstalk between GPCR and EGFR was
mediated by the activity of a RTK, not necessarily
EGFR. In contrast to AP-1, LPA stimulated another pro-
minent transcription factor NF-B via the Gq-PKC cas-
cade in an EGFR-independent manner. These results
demonstrate the involvement of EGFR or an alternate
RTK in activation of selective G protein signaling cas-
cades and the downstream responses.
Methods
Materials
1-oleoly (18:1) LPA and sphingosine 1 phosphate (S1P)
were obtained from Avanti Polar Lipids, Inc. (Alabaster,
AL). Prior to use, these phospholipids were dissolved in
PBS containing 0.5% fatty acid-free bovine serum albu-
min (BSA). BSA, Fugene 6 and protease inhibitor cock-
tail tablets were purchased from Roche (Indianapolis,
IN). Plasmid DNA was purified using the endo-free pur-
ification kit from Qiagen (Valencia, CA). Oligonucleo-
tides and primers were synthesized by Operon
Biotechnologies, Inc. (Huntsville, AL). Anti-phospho
NF-B p65 (Ser 536), anti-phospho IBa (Ser 32), anti-
phospho PKD (Ser 916), anti-phospho EGFR (Y 1068),
anti-phospho tyrosine (Y-p), anti-Ras, and anti-tubulin
a/b antibodies were obtained from Cell Signaling (Dan-
vers, MA). Anti-EGFR antibody recognizing Ala351-
Asp364 of the human EGF receptor was obtained from
Millipore (Billerica, MA). Insulin, TRIzol and cell cul-
ture reagents were obtained from Invitrogen Inc. (Carls-
bad, CA). Fetal bovine serum (FBS) was from Atlanta
Biologicals (Lawrenceville, GA). Insulin-like growth
factor (IGF) was obtained from Upstate Biotechnology
(Lake Placid, NY). Hepatocyte growth factor (HGF) and
the Quantikine IL-8 ELISA kit were obtained from R &
D systems (Minneapolis, MN). Epidermal growth factor
(EGF), platelet derived growth factor (PDGF), AG1478
and anti-b actin monoclonal antibody were obtained
from Sigma (St. Louis, MO). Other antibodies used were
from Santa Cruz Biotechnology (Santa Cruz, CA).
Reporter vectors and luciferase assays
The AP-1 responsive reporter vector pGL2-3xAP-1-TK-
Luc was constructed as described previously [15]. The
NF-B responsive luciferase vector p5xNF-B-Luc was
obtained from Stratagene (La Jolla, CA). Cells were
seeded in 6-well plates and transfected with luciferase
vectors using transIT-TKO transfection reagent (Mirus
Bio Corp., Madison, WI) according to the manufacturer.
After 48 hours, the cells were starved for 24-36 hours
before stimulation with 10 μM LPA or vehicle for 6
hours. Cell extracts assayed for luciferase activity using
the luciferase assay kits from Promega. The luciferase
activity was normalized on the basis of the activity of
co-transfected b-galactosidase reporter driven by the
cytomegalovirus promoter (pCMVb-gal).
Cell Culture
The sources and maintenance of ovarian cancer cell
lines used in the study were described previously
[15,19].
Western blotting
Cells were lysed in SDS sample buffer or in ice-cold X-
100 lysis buffer [1% Triton X-100, 50 mM HEPES (pH
7.4), 150 mM NaCl, 1.5 mM MgCl2,1m ME G T A ,1 0 %
glycerol, 100 mM NaF, 10 mM Na PPi, and protease
inhibitor cocktail]. Total cellular proteins were resolved
by SDS-PAGE, transferred to Immun-Blot membrane
[poly(vinylidene difluoride)] (BIO-RAD, Hercules, CA),
and immunoblotted with antibodies following the proto-
cols of manufacturers. Immunocomplexes were visua-
lized with an enhanced chemiluminescence detection kit
from Amersham (Piscataway, NJ).
Adenovirus and plasmids
The recombinant adenovirus carrying a truncated
EGFR-CD533 lacking the 533 amino acids at the cytoso-
lic domain was purified and used to infect cancer cell
lines as described previously [24]. The truncated form of
EGFR was also amplified by RT-PCR from Caov-3 cells
using primers: EGFR-DN-Fwd 5’ CATAAGCTTGG-
AGCAGCGATGCGACCCTCC 3’ and EGFR-DN-Rev 5’
CATCTCGAGGCGCTTCCGAAC-GATGTGG3’.T h e
fragment was cloned into the pcDNA3 expression vec-
tor. The Gq cDNA in pcDNA3 was kindly provided by
Dr. RD Ye (University of Illinois at Chicago). The domi-
nant-negative G208A mutant [25,26] was made by using
t h eQ u i k C h a n g eX Ls i t ed i r e c t e dm u t a g e n e s i sk i tf r o m
Stratagene.
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LPA-stimulated or control cells were washed twice
with cold PBS, harvested by scraping with a rubber
policeman and centrifuged at 1000 rpm for 3 min with
an Eppendorf microcentrifuge. Cell pellets were resus-
pended in a hypotonic lysis buffer [10 mM Tris-HCl
(pH 7.4), 10 mM KCl, 3 mM MgCl2,0 . 5 %N P - 4 0 ] ,
incubated for 15 min on ice, and centrifuged at 3000
rpm. The pellets were washed once with the hypotonic
lysis buffer, resuspended in hypertonic nuclear lysis
buffer [50 mM Tris-HCl (pH 8.3), 0.4 M NaCl, 40%
glycerol, 5 mM MgCl2 a n d0 . 1m ME D T A ]a n df u r t h e r
incubated for 10 minutes before centrifugation at
13,000 rpm. The supernatants were collected and
quick-frozen in liquid nitrogen before storage at -80°C.
Protein concentrations were determined with the
Pierce BCA kit.
AP-1 and NF-B consensus oligonucleotides (AP-1
sense 5’ GGCGCTTGATGACTCA-GCCGGAA 3’;A P - 1
antisense 5’GGTTCCGGCTGAGTCATCAAGCG 3’;
NF-B sense 5’ATGTTGAGGGGACTTTCCCAGGCGG
3’ and NF-Ba n t i s e n s e5 ’ GCCTGGGAAAGTC-
CCCTCAACTGG 3’) were annealed in 20 mM Tris (pH
7.4), 1 mM dithiothreitol, 50 mM NaCl and 10 mM
MgCl2. Oligonucleotides were labeled by filling in at 3’
end with [a-
32P] dCTP using Klenow. The probe and
protein binding was analyzed by incubating 4 μgo f
nuclear proteins in gel shift assay buffer [10 mM HEPES
(pH 7.8), 10% glycerol, 1 mM EDTA, 25 mM MgCl2,5 0
mM KCl, 1 μgo fp o l y ( d I . d C ) ,3μgB S Aa n dp r o t e a s e
inhibitors] in a final volume of 20 μL for 10 min at 25°
C. The binding specificity was confirmed by cold com-
petition with 50-fold excess of unlabeled oligonucleo-
tides. Complexes were separated by electrophoresis on
5% non-denaturing polyacrylamide gel (PAGE). Gels
were dried under vacuum and subjected to autoradio-
graphy using a phosphoimager.
Rho and Ras activation assays
Activation of Rho and Ras was analyzed by glutathione
S-transferase (GST) pulldown assays [27,28]. The cells
w e r eg r o w ni n1 0 - c md i s h e st osubconfluency, starved
overnight, and stimulated with LPA or vehicle. The cells
were lysed in Magnesium-containing lysis buffer MLB
(25 mM HEPES, pH 7.5, 150 mM NaCl, 1% NP40, 10%
glycerol, 10 mM MgCl2, 1 mM EDTA, 1 mM sodium
orthovanadate, 10 μg/ml leupeptin, 10 μg/ml aprotinin).
Clarified lysates were incubated for 45-60 minutes at 4°
C with GST-Rhotekin-RBD (Rho binding domain of the
mouse Rhotekin, residues 7-89) [28] or GST-Raf-RBD
(Ras binding domain of the human Raf, residues 1-149)
[27] produced in Escherichia coli and immobilized onto
glutathione-coupled Sepharose beads. Beads were
washed in MLB three times, eluted with SDS sample
buffer, and analyzed by immunoblotting.
Migration and invasion assays
The migration of SKOV-3 cells was assayed using trans-
well chambers (pore size 8 μM) (BD Biosciences, Bed-
ford, MA) as we described recently [29]. The inserts
were precoated with type I collagen. Serum-starved cells
were loaded to the upper chamber with or without
AG1478. LPA was added to the lower chambers. Non-
migrated cells were removed from the top filter surface
with a cotton swab. Migrated cells attached to the
underside of the transwells were washed with PBS and
stained with crystal violet and counted under a micro-
scope. The invasion of SKOV-3 cells was measured
using transwells coated with growth factor-reduced
basement membrane matrix (pore size 8 μM) (BD
Biosciences).
Wound Closure Assay
Confluent monolayers of Caov-3 were serum starved for
18 hours. Scratches were made using sterile pipette tips.
Displaced cell debris was washed off with serum-free
media before stimulation with LPA or BSA with or
without AG1478.
Statistics
All numerical data were presented as mean ± SD. The
statistical significance of differences was analyzed using
Student’s t test where p < 0.05 was considered statisti-
cally significant.
Results
Activation of AP-1 proteins by LPA, EGF or HGF
LPA is a master inter-cellular regulator of gene expres-
sion in mammalian cells, especially in human cancer
cells that express multiple LPA receptor subtypes
[15,17,19,20,30]. Although post-transcriptional regula-
tion may be involved in the reinforcement of the LPA’s
effect on gene expression [19], the major activity seems
to be afforded by transcriptional upregulation. We have
shown that a number of transcription factors such as C/
EBP, NF-B, AP-1, c-Myc and Sp-1 individually or coor-
dinately initiate transcription of LPA target genes
[15,19,20]. Thus analysis of transcriptional activation
offers an ideal readout to study functionality of LPA
receptors, their downstream signaling networks and
their crosstalk with RTKs. In ovarian and other cancer
cell lines, treatment with LPA led to induction of multi-
ple AP-1 proteins. As demonstrated in Fig. 1A, LPA
induced c-Jun, Jun-B, c-Fos, and Fra-1 proteins in a
time-dependent manner in Caov-3 cells. LPA also trig-
gered phosphorylation of c-Jun and c-Fos (data not
shown). Induction of c-Jun and c-Fos expression peaked
at 1-2 hours after exposure to LPA. Jun-B and Fra-1
were induced later and the highest levels were observed
at 4-6 hours of LPA treatment (Fig. 1A).
The sequential induction of these AP-1 components
could lead to sustained increases in AP-1 activity.
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ing activity in LPA-treated cells, which lasted for many
hours (Fig. 1B). Consistent with early induction of c-Jun
and c-Fos and delayed induction of Jun-B and Fra-1,
AP-1 DNA-binding activity was increased at 0.5 hour,
reached plateau at 1 hour and remained at the highest
levels up to 6 hours after addition of LPA. We further
confirmed that LPA treatment resulted in transcriptional
activation of AP-1. Caov-3 cells were transfected with
the AP-1 responsive luciferase reporter pGL2-3xAP-1-
TK-Luc. Treatment with 10 μML P Af o r6h o u r s
induced more than 25-fold increases in luciferase activ-
ity compared to vehicle-treated cells (see Fig. 3C).
In these experiments, we also analyzed EGF and HGF
for their ability to activate AP-1. The effects of LPA on
AP-1 protein expression and AP-1 DNA-binding activity
were stronger or at least comparable to those of EGF
(Fig. 1). Since LPA induced only nominal EGFR activa-
tion as reflected by a modest increase in EGFR phos-
phorylation at Y1068 or in overall tyrosine
phosphorylation of EGFR as surrogate measurement of
EGFR activation (Fig. 2), it is unlikely that LPA stimu-
lated AP-1 through transactivated EGFR. Compared to
HGF, LPA was much more efficacious in inducing each
of AP-1 proteins (Fig. 1A) and in increasing AP-1 DNA-
binding activity (Fig. 1B). For example, HGF only
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Figure 1 Activation of AP-1 by LPA, EGF or HGF. A. Caov-3 cells were starved and stimulated for the indicated periods of time with LPA (10
μM), EGF (25 ng/ml) or HGF (20 ng/ml). The cell lysates were analyzed by immunoblotting for expression of AP-1 proteins c-Jun, c-Fos, Jun-B
and Fra-1 and other loading controls (lamin A/C, b actin or tubulin). B. Caov-3 cells were stimulated as in A and analyzed for AP-1 DNA binding
activity with EMSA by incubating with
32P-labeled AP-1 consensus oligonucleotides. Reaction mixes were run on 5% native polyacrylamide gels
and autoradiographed. The specificity of binding to the
32P-labeled AP-1 probe in nuclear extracts of cells treated with LPA for 2 hours was
confirmed by inhibition of the binding with 50 times of unlabeled oligonucleotides (cold competition).
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Figure 2 Modest increase in tyrosine phospho r y l a t i o no fE G F Ri n d u c e db yL P A . A. Caov-3, Dov-13 and SKOV-3 cells were staved and
stimulated for 30 min or otherwise indicated (hr) with LPA (10 μM), S1P (1 μM), LPA (10 μM)+S1P (1 μM) IGF (50 ng/ml), insulin (0.2 μM), PDGF
(BB isoform, 50 ng/ml), EGF (25 ng/ml) or FBS (5%). Tyrosine phosphorylation of EGFR was examined by immunoblotting with an anti EGFR
phospho-specific antibody that recognizes EGFR-p at Y1068. The membrane was reprobed for total EGFR or b actin. In the bottom panel, Caov-3
and OVCAR-3 cells were treated with LPA (10 μM) for the indicated periods of time (min) or with EGF (25 ng/ml) for 30 min as a positive
control. EGFR was immunoprecipitated from cell lysates and then analyzed by immunoblotting with an anti phosphotyrosine antibody for
tyrosine phosphorylation (Y-p). B. Caov-3 cells were treated with LPA or different doses of EGF as indicated. Induction of AP-1 proteins and
EGFR-p was examined by immunoblotting.
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Page 5 of 13modestly stimulated expression of c-Jun, c-Fos, Jun-B
and failed to induce Fra-1 (Fig. 1A). Accordingly, only a
weak and transient increase in AP-1 DNA-binding activ-
ity was detected in HGF-treated cells compared to that
seen in LPA-stimulated cells (Fig. 1B).
Requirement of EGFR or an alternate RTK for LPA
activation of AP-1
Transactivation of EGFR does not seem to account for
the dramatic stimulation of AP-1 activity by LPA (Fig.
2). However, pretreatment of Caov-3 cells with
AG1478, a specific pharmacological inhibitor of EGFR
kinase activity [31] abrogated expression of Jun-B and
Fra-1 and dramatically decreased c-Fos and c-Jun
expression in LPA-treated cells (Fig. 3A). In agreement
with the inhibition of AP-1 protein expression,
AG1478 also dramatically suppressed LPA-stimulated
AP-1 DNA-binding and transcriptional activities in
Caov-3 cells (Fig. 3C &3D). Similar results were
obtained from the SKOV-3 and Dov-13 ovarian cancer
cell lines (data not shown).
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Figure 3 Requirement of EGFR or an alternate receptor tyrosine kinase for LPA-induced activation of AP-1. A. LPA-induced expression of
AP-1 proteins was suppressed by the EGFR inhibitor AG1478, an effect reversible by costimulation with HGF. Caov-3 cells were starved and
stimulated with LPA in the presence of vehicle, AG1478 (LPA/AG1478), or AG1478 and HGF (LPA/HGF/AG1478). AG1478 (1 μM) was added 45
min before stimulation with LPA (10 μM) or LPA plus HGF (20 ng/ml). AP-1 proteins and the loading control GSK-3a/bwere analyzed by
immunoblotting. The results were quantified by densitometry with values of the un-stimulated, control cells in each set of treatment defined as
1 fold. ND refers to signals not detectable. Similar results were obtained from two independent experiments. B. LPA-induced expression of AP-1
proteins was also inhibited by a dominant negative mutant of EGFR (EGFR-DN). EGFR-DN was expressed in Caov-3 cells via adenovirus (left panel)
or transient transfection (right panel). The recipient cells were starved and stimulated for the indicated periods of time with 10 μM LPA followed
by immunoblotting for expression of AP-1 proteins, phosphorylated p65, and EGFR-DN. C. LPA-induced AP-1 DNA-binding activity was
dependent on EGFR or an alternate RTK. Nuclear extracts were prepared from Caov-3 cells treated for the indicated periods of time with LPA in
the presence of vehicle (DMSO), AG1478, or AG1478 plus HGF as described in A. The AP-1 DNA-binding activity of nuclear extracts was analyzed
with EMSA. D. The AP-1 transcriptional activity was sensitive to AG1478. Caov-3 cells were transfected with the AP-1 reporter vector pGL2-3xAP1-
TK-Luc. The cells were starved and stimulated for 6 hours with LPA (10 μM) in the presence of AG1478 (1 μM) or vehicle. Luciferase activity in
cell lysates was determined with luciferase assay kits and the results expressed as fold induction with the basal activity in unstimulated control
cells defined as 1 fold. The statistical significance of differences of data in this and following figures was determined by Student’s t test, where p
< 0.05 was considered statistically significant and marked with an asterisk.
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EGFR instead of toxic or non-specific interference with
other targets, we expressed a truncated form of EGFR
(EGFR-CD533) lacking the cytosolic domain and thereby
functioning as a dominant negative mutant (EGFR-DN)
through dimerization with wild type EGFR [24]. EGFR-
DN was introduced into Caov-3 cells using adenovirus
expressing EGFR-DN [24] or by transient transfection of
pcDNA3-EGFR-DN with Amaxa nuocleofector Kit T
that yield high transfection efficiency in ovarian cancer
cell lines as we described previously [19]. As shown in
Fig. 3B, expression of EGFR-DN indeed inhibited LPA-
induced expression of AP-1 proteins. These results
demonstrated that an intact EGFR is indispensable for
LPA activation of AP-1.
To address whether EGFR, instead of other RTKs, is
specifically required for GPCR signaling to AP-1, we co-
stimulated Caov-3 cells with LPA and HGF, an agonist
of c-Met, in the presence of the EGFR blocker AG1478.
As shown in Fig. 3A, the inhibitory effect of AG1478 on
AP-1 proteins was reversed by co-stimulation of the
cells with LPA and HGF. LPA-induced AP-1 DNA bind-
ing activity was also restored by HGF in the presence of
AG1478 (Fig. 3C). The impact of HGF was not due to
activation of AP-1 proteins by HGF itself as the effect of
HGF on AP-1 was marginal compared to that of LPA
(Fig. 1A &1B). These results indicate that the activity of
a RTK, not necessarily EGFR, provides a permissive
input to allow transmission of GPCR signals to AP-1
although such an input itself is not sufficient to induce
full AP-1 activation.
EGFR-independent activation of NF-B by LPA
The role of EGFR in LPA induction of AP-1 activity
raises the possibility that EGFR might be required ubi-
quitously for GPCR actions. This could be due to the
requirement of a RTK activity for overall functioning of
GPCR. However, if the RTK input is implicated in acti-
vation of the specific intracellular signaling processes
instead of GPCR itself, certain LPA signaling pathways
may be exceptional to this requirement. To distinguish
these possibilities, we examined LPA-induced activation
of NF-B, another prominent transcription factor criti-
cally involved in activation of many LPA target genes
[15]. In Caov-3 treated with AG1478 or overexpressing
EGFR-DN, LPA induced NF-B p65 phosphorylation
(Ser 536), IBa phosphorylation (Ser 32) and IBa
degradation at levels comparable to those detected in
control cells with intact EGFR (Fig. 4A &4B). Similarly,
LPA-stimulated NF-B DNA-binding activity was not
compromised by AG1478 as measured by EMSA (Fig.
4C). Nor was LPA-driven NF-B transcriptional activity
significantly affected by incubation of cells with AG1478
as analyzed by the NF-B responsive luciferase reporter
assay (Fig. 4C). Therefore, in sharp contrast to AP-1
upregulation, LPA-induced NF-B activation occurs via
an EGFR-independent route. The results also indicate
that the crosstalk with RTK is required only for a selec-
tive subset of biochemical events downstream of LPA
receptors but not ubiquitous receptor activation.
G protein cascades mediating AP-1 and NF-B activation
To identify the mechanism for the differential require-
ments of RTK in the delivery GPCR signals to AP-1 and
NF-B, we examined G protein cascades regulating AP-
1 and NF-B activation. The classical Edg LPA receptors
expressed in cancer cell lines couple to Gi, Gq and G12/
13 [4-7]. Pertussis toxin (PTX), a selective inhibitor of
Gi proteins, strongly decreased LPA-induced AP-1 pro-
teins c-Jun and c-Fos as shown in Fig. 5A, indicating
that the Gi signaling links to AP-1 activation by LPA.
However, Gi was dispensable for NF-B activation as
PTX did not alter NF-B p65 phosphorylation induced
by LPA in these cells (Fig. 5A).
To assess the contribution of Gq signaling to AP-1
and NF-B activation, we used a dominant negative
form of Gq (G208A) that has been shown to specifically
block Gq-mediated pathways in different cell systems
[25,26]. The Gq-DN mutant (pcDNA3-GqG208A) was
transfected into Caov-3 cells using Amaxa. Expression
o ft h eG qm u t a n ta l m o s tc o m p l e t e l yp r e v e n t e dL P A -
induced NF-B p65 phosphorylation (Fig. 5B). It also
strongly decreased c-Fos expression and slightly
decreased c-Jun induction in response to LPA (Fig. 5B).
Because of the lack of commercially available inhibitor
of Gq, these effects on c-Jun, c-Fos and NF-Bp 6 5o f
GqG208A were further confirmed by using U73122
[32], an inhibitor of phospholipase C that lies down-
stream of Gq (Fig. 5C). Therefore, the Gq-mediated sig-
naling is critical for LPA stimulation of NF-Ba n d
contributes to LPA induction of the AP-1 component c-
Fos.
We also examined the role of G12/13 in LPA-
mediated activation of AP-1 and NF-B by inhibition of
the G12/13 effector ROCK. ROCK has been reported to
participate in LPA-induced c-Jun expression in NIH
3T3 cells [33]. We examined the effect of the specific
ROCK inhibitor Y27632 on LPA-induced AP-1 and NF-
B activation. The compound did not affect LPA-
induced p65 phosphorylation but compromised c-Jun
and c-Fos induction (Fig. 5C). Based on these results,
each of G protein modules (Gi, Gq, and G12/13) seems
to contribute to AP-1 activation but only Gq couples to
the NF-B activation in LPA-stimulated cells.
Differential requirement of EGFR for activation of G
protein cascades
We next explored whether EGFR is differentially
required for activation of the diverse G protein signaling
modules. Since it is practically difficult to quantitate
activation of different classes of G proteins, we
Oyesanya et al. Molecular Cancer 2010, 9:8
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G proteins. Specifically, Ras is a well-defined Gi-depen-
dent signal [4,12]. Rho activation lies downstream of
G12/13 [5,12]. Gq activation could be monitored by
analyzing the downstream PKC-PKD pathway [34]. GST
pulldown assays were employed to analyze LPA-trig-
gered Ras and Rho activation [27,28]. As demonstrated
in Fig. 6A, AG1478 abolished LPA-induced Ras activa-
tion as suggested by loss of GTP-bound Ras (GTP-Ras)
in LPA-stimulated cells. Ina g r e e m e n tw i t hE G F R -
dependent activation of Ras by LPA, Gi-linked Erk acti-
vation was also inhibited by AG1478 (data not shown),
suggesting that Gi activation by LPA relies on a permis-
sive signal from EGFR. However, the presence of
AG1478 did not interfere with LPA-induced increases in
Rho-GTP (Fig. 6A), indicating that EGFR activity is not
essential for activation of the Rho-ROCK pathway. Simi-
larly, inhibition of EGFR with AG1478 did not impair
signal transmission from Gq to PKD as reflected by the
retention of a full magnitude of PKD phosphorylation
(Ser 916) induced by LPA (Fig. 6B). LPA-stimulated
PKD phosphorylation was suppressed by the PKC inhi-
bitor GF 109203X (Fig. 6B), which also attenuated NF-
B p65 phosphorylation in response to LPA (Fig. 6B).
Therefore, activation of the Gq-PLC-PKC pathway and
the downstream NF-B by LPA does not require EGFR.
These results reveal EGFR-dependent Gi and EGFR-
independent Gq and G12/13 signaling cascades down-
stream of LPA receptors. Since these G protein cascades
are coupled to specific transcription factors as identified
above, the results provide a molecular basis for the dif-
ferential requirement of EGFR in LPA activation of AP-
1 and NF-B.
Roles of EGFR in multiple biological responses to LPA
If Gi and the downstream AP-1 depend on an EGFR
permissive signal for activation, we expected that many
cellular processes mediated by Gi or AP-1 would be
sensitive to inhibition of EGFR. To further test this
Figure 4 EGFR-independent activation of NF-B by LPA. A. LPA-induced NF-B activation was resistant to AG1478. Caov-3 cells were starved
and stimulated for the indicated periods of time with LPA (10 μM) in the presence of AG1478 (1 μM) or vehicle (DMSO). AG1478 was added 45
min before stimulation with LPA. NF-B p65 phosphorylation at Ser 536, IBa degradation and total IKKa/b (left panel), and IBa
phosphorylation at Ser 32 (right panel) were analyzed by immunoblotting. B. LPA-induced NF-B activation was refractory to expression of EGFR-
DN. EGFR-DN was introduced into Caov-3 cells via recombinant adenovirus (left panel) or transient transfection (right panel) and expressed as
shown in Fig. 3B. LPA-induced p65 phosphorylation was analyzed by immunoblotting. C. LPA-induced NF-B DNA-binding and transcriptional
activities were unaffected by inhibition of EGFR. Nuclear extracts were prepared from Caov-3 cells stimulated for the indicated periods of time
with LPA (10 μM) in the presence of AG1478 or vehicle as in A. The NF-B DNA binding activity was determined with EMSA (left panel). LPA-
induced NF-B transcriptional activity was analyzed by luciferase assay (right panel). The cells were transfected with p5xNF-B-Luc, starved and
stimulated for 6 hours with LPA (10 μM) in the presence of AG1478 (1 μM) or vehicle. The results were presented as fold induction with the
basal activity in unstimulated cells defined as 1 fold.
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on LPA-induced IL-8 production, a functional outcome
of synergistic activation of NF-Ba n dA P - 1a sw e
described previously [15]. Although EGF its own only
weakly stimulated IL-8 generation [15], the prominent
effect of LPA was suppressed by inhibition of EGFR
with AG1478 (Fig. 7A). The data was consistent with
participation of EGFR in LPA-induced AP-1 activation
and the subsequent IL-8 production.
Due to the crucial role of Gi-mediated signals in promo-
tion of cell proliferation and motility [12,29,35], one would
predict that these biological responses to LPA should be
also attenuated by inhibition of EGFR. Indeed, as shown in
Fig. 7B, AG1478 significantly decreased LPA-stimulated
cell growth in Caov-3 and SKOV-3 cells. AG1478 also
inhibited LPA-induced migration and invasion of these
cells as assessed in transwell chambers in SKOV-3 cells or
by wound healing assay in Caov-3 cells (Fig. 7C &7D).
Figure 5 Involvement of different G protein signaling cascades in LPA-induced activation of AP-1 and NF-B. A. Inhibition of Gi with
PTX attenuated AP-1 but not NF-B activation by LPA. Caov-3 cells were starved and stimulated for the indicated periods of time with LPA (10
μM) in the presence or absence of PTX (25 ng/ml). PTX was added 6 hours before stimulation with LPA. LPA-induced phosphorylation of NF-B
p65 at Ser 536 and expression of c-Jun and c-Fos were analyzed by immunoblotting. B. Caov-3 cells were transfected using Amaxa with the Gq
G208A dominant negative mutant (Gq-DN) or control vector. The transfected cells were starved and stimulated for 2 hr with LPA (10 μM) before
immunoblotting for p65 phosphorylation and c-Jun and c-Fos expression. C. Caov-3 cells were starved and stimulated for indicated periods of
time with LPA (10 μM) in the presence or absence of U73122 (10 μM) or Y27632 (7.5 μM) which were added 45 min before stimulation with
LPA. NF-B p65 phosphorylation and c-Jun and c-Fos expression were assessed by immunoblotting. Reprobing with tubulin or b actin was
included as loading controls.
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Figure 6 Differential requirement of EGFR for activation of G protein signaling cascades by LPA. A. Inhibition of EGFR blocked LPA-
stimulated Ras but not Rho activation. Caov-3 cells were starved and stimulated for the indicated periods of time with LPA (5 μM) in the
presence of AG1478 (1 μM) or vehicle (DMSO). The levels of Ras-GTP and Rho-GTP were determined by pulldown with GST-Raf and GST-
Rhotekin, respectively as described in Methods. B. Inhibition of EGFR did not affect signaling of the Gq-PKC pathway. Caov-3 cells were starved
and stimulated for the indicated periods of time with LPA (10 μM) in the presence of AG1478 (1 μM), GF109203X (2.5 μM) or vehicle. LPA-
induced phosphorylation of PKD at Ser 916 and NF-B p65 at Ser 536 was analyzed by immunoblotting followed by reprobing with b actin.
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We have previously shown that LPA induces transcrip-
tional activation of multiple cancer-associated genes
[15,17,19,20]. In these studies, ovarian cancer cells were
used as a model system that express multiple LPA
receptor subtypes and respond robustly to physiological
levels of LPA. We demonstrated that LPA drives gene
expression via a broad range of transcription factors
[15,17,19,20]. However, the signaling processes linking
LPA to transcriptional activation remain poorly
understood. In the current study, we have focused on
the crosstalk between LPA receptors and EGFR in G
protein signaling to transcription factors. Our results
indicate that LPA-induced activation of AP-1 relies on a
permissive activity from EGFR while LPA stimulates
NF-Bi na nE G F R - i n d e p e n d e n tm a n n e r .T h ed i f f e r e n -
tial requirements of EGFR for AP-1 and for NF-Bs u g -
gest that the EGFR signal is involved in activation of a
subset of intracellular signaling cascades of LPA recep-
tors rather than the overall functionality of LPA recep-
tors. Furthermore, we identified EGFR-dependent and
Figure 7 Participation of EGFR in LPA-induced IL-8 production, cell proliferation, migration and invasion. A. Caov-3 cells cultured in 6-
well plates were starved and stimulated for 16 hours with LPA (10 μM) in the presence of indicated concentrations of AG1478. Levels of IL-8
released to culture supernatants were analyzed by ELISA. B. Caov-3 and SKOV-3 cells were cultured in 6-well plates with serum-free medium
supplemented with EGF (25 ng/ml) or with 5 μM LPA in the presence of AG1478 (1 μM) or vehicle for 1-3 days. The cell numbers from triplicate
wells were determined daily with a coulter counter. C. Caov-3 cells were grown in 60 mm dishes to confluence and starved before scratches
were made with sterile pipettes. The cells were incubated for 16 hours with BSA or LPA (5 μM) in the presence of AG1478 (1 μM) or vehicle.
Microscopic images (76×) were captured at 0 and 16 hours after LPA exposure. D. The migration and invasion of SKOV-3 cells in response to
EGF (25 ng/ml) or to LPA (1 μM) in the absence or presence of AG1478 (1 μM) were analyzed using transwells and transwells coated with
growth factor-reduced basement membrane matrix, respectively. SKOV-3 cells were starved with or without AG1478 before trypsinization. The
cells (2.5 × 10
4 cells/0.5 ml for migration and 1 × 10
5/0.5 ml for invasion) were loaded to the upper chambers and allowed to migrate for 6
hours or invade for 20 hours. The migrated and invaded cells on the underside of transwells were stained with crystal violet and counted under
microscope. Results were average numbers of migrated or invaded cells/transwell from triplicates (mean+ SD). The data shown was
representative of three independent experiments.
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activation of the AP-1 and NF-B transcription factors.
Our results establish that the Gi-mediated pathway
relies on EGFR for activation while Gq and G12/13 sig-
nals are refractory to inhibition of EGFR. AP-1 activa-
tion by LPA involves signaling of Gi, Gq, and G12/13
and therefore is EGFR dependent. On the other hand,
activation of NF-B by LPA is mediated through an
EGFR-independent Gq signaling process with little con-
tribution from Gi or G12/13 pathway.
The crosstalk between RTK and GPCR in cellular
functions has been a subject of extensive research in the
area of signal transduction. The “transactivation” model
has been proposed to explain the functional dependence
of GPCR signals on RTK [21,22]. In contrast, the possi-
bility for integration of RTK activity into specific signal-
ing events of GPCR has been suggested but poorly
studied [19,36]. In ovarian cancer cell lines challenged
with LPA, we observed only weak transactivation of
EGFR (Fig. 2). In addition, the effects of LPA on activa-
tion of transcription factors and the downstream gene
expression were more profound than those of EGF
[15,17,19]. Therefore, it is hard to imagine that LPA
induces these biochemical and biological changes purely
through transactivated EGFR. In contrast, our results
are in concert with a permissive role of EGFR in activa-
tion of a subset of GPCR signals. Elucidation of EGFR-
dependent and EGFR-independent G protein signaling
cascades and their downstream biochemical events allow
us to conclude that only selective GPCR signaling path-
ways are regulated by EGFR.
It remains to be determined how EGFR is integrated
with GPCR signaling to activate Gi and the downstream
processes. The EGFR signal may feed in at Gi or at
some points of the Gi axis. EGFR may be required for
tyrosine phosphorylation of Gi or another component of
the Gi pathway. Since the role of EGFR could be substi-
tuted for by activation of another RTK such as c-Met, it
is unlikely that EGFR physically interacts with LPA
receptors to facilitate Gi activation. Most likely, a RTK
activity, not necessarily EGFR, catalyzes critical tyrosine
phosphorylation of Gi or a Gi effector protein.
Compared to other RTKs, EGFR is more universally
expressed and exhibits higher activity, particularly in
cancer cells [37]. EGFR is amplified, overexpressed or
activated through mutation in many types of human
cancers including ovarian cancer [37,38]. Therefore
EGFR is a well-recognized anti-cancer therapeutic target
[37,38]. The elevated EGFR activity in malignant cells
likely acts as a default RTK to crosstalk with GPCR.
The basal, unstimulated activities of other RTKs may
not be sufficient to serve such a role. However, when
activated by their specific ligands, other RTKs such as c-
Met can replace EGFR to provide a tyrosine kinase
activity to allow GPCR signaling to Gi and the down-
stream networks. Based on our results presented in the
current study, EGFR is essential for many biological pro-
cesses evoked by GPCRs including cytokine production,
cell proliferation, and cell migration and invasion.
Diverse GPCR agonists are important mediators of can-
cer initiation and progression. Inhibition of EGFR in
cancer patients may provide therapeutic benefits
through not only disconnecting EGFR to its own direct
effectors but also interfering with GPCR signaling.
Conclusions
We have demonstrated that EGFR is required for activa-
tion of the AP-1 transcription factor and other Gi-
dependent cellular responses to LPA. In contrast, activa-
tion of G12/13, Gq and Gq-elicited NF-B by LPA is
independent of EGFR signaling. This selective require-
ment of EGFR reflects engagement of a permissive sig-
nal from a RTK, not necessarily EGFR, in LPA
activation of a subset of G protein cascades. These
results provide a novel insight into the role of RTK in
GPCR signal transduction and biological functions.
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